Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of PF-06412562 MR Formulation in Healthy Subjects
NCT02201511Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of razpipadon in schizophrenia and Parkinson's disease (PD) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration, Time to Reach Maximum Observed Plasma Concentration and 4 more. Started Sep 2014; status: completed.
02
Drugs
razpipadon
03
Conditions
schizophreniaParkinson's disease (PD)
Beyond the preview
Go deeper on NCT02201511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02201511.